Completing data — refresh the page later to see the latest
461443-59-4CCCCN1C(=O)[C@@H]([C@H](O)C2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccc(C(=O)O)cc3)cc1)CC2GWNOTCOIYUNTQP-FQLXRVMXSA-NA spiro-diketo-piperazine; a potent noncompetitive allosteric antagonist of the CCR5 receptor with concomitantly potent antiviral effects for HIV-1.
461443-59-4DTXSID6047317CHEMBL1255794Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
Drug Induced Liver Injury Rank (DILIrank 2.0)
Aplaviroc
vMost-DILI-concern
8
Discontinued
DOI:10.1016/j.drudis.2016.02.015
GW873140 is a novel CCR5 receptor antagonist that binds specifically to human CCR5. It binds to human CCR5 with a unique profile as evidenced by the selective inhibition of monoclonal antibody binding. One of the many ways in which CCR5 inhibitors differ from the currently available classes of HIV drugs is that they bind to the host (CCR5 receptor), the cell, target rather than to the viral enzymes in cells like the CD4 cell.
UsesTreatment of HIV infection.